4k1l: Difference between revisions

Revision as of 20:05, 17 April 2013 view source OCA (talk \| contribs) Bots, Bureaucrats, journal, Administrators 3,332,843 edits m Protected "4k1l" [edit=sysop:move=sysop] ← Older edit		Revision as of 07:17, 8 May 2013 view source OCA (talk \| contribs) Bots, Bureaucrats, journal, Administrators 3,332,843 edits No edit summary Newer edit →
Line 5:		Line 5:
	Authors: Loenze, P., Schimanski-Breves, S., Von der Heyden, C., Engel, C.K.		Authors: Loenze, P., Schimanski-Breves, S., Von der Heyden, C., Engel, C.K.

	Description: 4,4-Dioxo-5,6-dihydro-[1,4,3]oxathiazines, a novel class of 11 -HSD1 inhibitors for the treatment of diabetes		Description: 4,4-Dioxo-5,6-dihydro-[1,4,3]oxathiazines, a novel class of 11 beta-HSD1 inhibitors for the treatment of diabetes

Navigation menu